651744-40-0

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-ISOPROPYL-4-OXO-3,4-DIHYDROPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE is used as a potential pharmaceutical agent for its capacity to interact with various biological targets due to its complex molecular structure. Its specific application reasons and efficacy would require further investigation and clinical trials to confirm.
Used in Agricultural Industry:
In the agricultural sector, ETHYL 5-ISOPROPYL-4-OXO-3,4-DIHYDROPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE may serve as a component in the development of new agrochemicals, such as pesticides or herbicides, leveraging its structural diversity to target specific pests or weeds. The actual application and effectiveness would be subject to empirical testing and regulatory approval.
Given the current state of information, these uses are speculative and would necessitate substantial research and development to validate their feasibility and safety.

Upstream product

• 77287-34-4 formamide 
• 651744-39-7 diethyl 1-amino-3-(propan-2-yl)-1H-pyrrole-2,4-dicarboxylate 
• 104398-21-2 ethyl 4-(propan-2-yl)-1H-pyrrole-3-carboxylate 
• 2999-46-4 Ethyl isocyanoacetate 
• 651744-38-6 diethyl 3-(propan-2-yl)-1H-pyrrole-2,4-dicarboxylate 
• 15790-86-0 ethyl-4-methyl-2-(E)-penteneoate 

Downstream Products

• 658084-80-1 ethyl 4-chloro-5-iso-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 

Relevant academic research and scientific papers

Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors

A versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4] triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compounds with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5- (methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors

A series of substituted 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino) pyrrolo[2,1-f][1,2,4]-triazines was identified as potent and selective inhibitors of the tyrosine kinase activity of the growth factor receptors VEGFR-2 (Flk-1, KDR) and FGFR-1. The enzyme kinetics associated with the VEGFR-2 inhibition of compound 50 (Ki = 52 ± 3 nM) confirmed that the pyrrolo-[2,1-f][1,2,4]triazine analogues are competitive with ATP. Several analogues demonstrated low-nanomolar inhibition of VEGF- and FGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation. Replacement of the C6-ester substituent of the pyrrolo[2,1-f][1,2,4]-triazine core with heterocyclic bioisosteres, such as substituted 1,3,5-oxadiazoles, afforded compounds with excellent oral bioavailability in mice (i.e., 50 Fpo = 79%). Significant antitumor efficacy was observed with compounds 44, 49, and 50 against established L2987 human lung carcinoma xenografts implanted in athymic mice. A full account of the synthesis, structure-activity relationships, pharmacology, and pharmacokinetic properties of analogues within the series is presented.

New dual inhibitors of EGFR and HER2 protein tyrosine kinases

A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, has been developed. Biological evaluation in enzyma

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula I, (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as ant